Taking On Turing: Imprimis Aims For Drug Accessibility
This article was originally published in Scrip
Executive Summary
Imprimis Pharmaceuticals Inc. was thrust into the spotlight in late October when it declared it could make a compounded form of a toxoplasmosis medicine, pyrimethamine, available to patients for a significantly lower price than the $750 per pill Turing Pharmaceuticals AG is charging for its drug, which is sold as Daraprim.